BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$279.31 USD
+5.25 (1.92%)
Updated May 2, 2024 04:00 PM ET
After-Market: $279.20 -0.11 (-0.04%) 7:50 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$279.31 USD
+5.25 (1.92%)
Updated May 2, 2024 04:00 PM ET
After-Market: $279.20 -0.11 (-0.04%) 7:50 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
New Strong Sell Stocks for September 19th
by Zacks Equity Research
BIO, LPG and COLB have been added to the Zacks Rank #5 (Strong Sell) List on September 19, 2023.
New Strong Sell Stocks for August 18th
by Zacks Equity Research
BIO, REFI and GPK have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2023.
New Strong Sell Stocks for August 9th
by Zacks Equity Research
BWA, ARR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on August 9, 2023.
Bio-Rad (BIO) Beats on Q2 Earnings Estimates, Cuts 2023 View
by Zacks Equity Research
Growth across the Life Science portfolio and strong double-digit growth for ddPCR drive Bio-Rad (BIO) Q2 performance.
Bio-Rad Laboratories (BIO) Tops Q2 Earnings Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 17.65% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
SurModics (SRDX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 213.04% and 96.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?
by Zacks Equity Research
Bio-Rad Laboratories' (BIO) second-quarter 2023 results are likely to reflect an impressive performance across its Clinical Diagnostics business.
Are Options Traders Betting on a Big Move in Bio-Rad Laboratories (BIO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bio-Rad Laboratories (BIO) stock based on the movements in the options market lately.
Bio-Rad Laboratories (BIO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Bio-Rad Laboratories (BIO) closed at $377.68, marking a +0.09% move from the previous day.
Bio-Rad Laboratories (BIO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bio-Rad Laboratories (BIO) closed at $364.38 in the latest trading session, marking a -0.37% move from the prior day.
Bio-Rad Laboratories (BIO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bio-Rad Laboratories (BIO) closed at $364.78 in the latest trading session, marking a -0.46% move from the prior day.
Bio-Rad Laboratories (BIO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Bio-Rad Laboratories (BIO) closed the most recent trading day at $376.56, moving -0.66% from the previous trading session.
Bio-Rad Laboratories (BIO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bio-Rad Laboratories (BIO) closed at $361.03, marking a +0.43% move from the previous day.
Perrigo (PRGO) Down 7.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bio-Rad Laboratories (BIO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Bio-Rad Laboratories (BIO) closed at $372.36, marking a +0.27% move from the previous day.
Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses
by Zacks Equity Research
Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.
Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.
Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 3.09% and 0.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?
by Zacks Equity Research
The first-quarter results of Cigna (CI) are likely to reflect an expanding customer base and growth in specialty pharmacy services.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
Embecta (EMBC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
Charles River (CRL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
Are Medical Stocks Lagging BioRad Laboratories (BIO) This Year?
by Zacks Equity Research
Here is how Bio-Rad Laboratories (BIO) and GSK (GSK) have performed compared to their sector so far this year.
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.